[Bioengineering] Short Oral Regimens for Rifampicin-Resistant TB: Efficacy and Safety

10 June 2026

Bioengineering news story

A study, published in Nature Communications, assessed the pharmacokinetics, bactericidal efficacy, and potential toxicities associated with novel short oral treatment regimens for rifampicin-resistant TB.

TB continues to claim millions of lives annually, with rifampicin-resistant strains posing a significant hurdle to global TB control efforts. Rifampicin, a cornerstone antibiotic in first-line TB treatment, loses its efficacy against such resistant strains, necessitating alternative regimens that are not only effective but also feasible and safe for widespread use. The emergence of short-course oral therapies offers hope for spurring higher treatment adherence, reducing adverse events, and potentially curbing transmission rates in high-burden settings.

Read the full news story here.

Source: Bioengineering